News & Events

News

All categories

Earnings

Press Release

All years

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells

May 13, 2021

Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress

April 15, 2021

Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I

April 12, 2021

Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

April 9, 2021

Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021

April 8, 2021

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

March 31, 2021

Affimed Announces Presentations at the AACR Annual Meeting 2021

March 10, 2021

Affimed Announces Continuation of REDIRECT, a Registration-directed Study of AFM13 in PTCL, after Positive Preplanned Interim Futility Analysis

March 10, 2021

Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors

February 3, 2021

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 15, 2021

Events

All

Scientific

Investors

02Nov

PEGS Europe

November 2 - 4, 2021 (Barcelona, Spain)

10Nov

SITC 2021

November 10 - 14, 2021 (Washington, D.C. (and virtual))

Webcasts
More events